Loading clinical trials...
Loading clinical trials...
A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy
Conditions
Interventions
Ofatumumab
Ofatumumab
Locations
1
United Kingdom
GSK Investigational Site
Southampton, United Kingdom
Start Date
May 1, 2007
Primary Completion Date
April 1, 2009
Completion Date
September 1, 2013
Last Updated
January 29, 2014
NCT06785818
NCT04911478
NCT06425302
NCT02278796
NCT00081809
NCT02376699
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions